University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

PMTCT Program Brief: Offering ARV Prophylaxis at Time of Diagnosis

Get This Resource

English: PDF [500K]

Summary

In many countries, single-dose nevirapine (SD-NVP) is the most commonly used ARV prophylactic regimen for PMTCT. It typically consists of one 200 mg tablet ingested by the mother at the onset of labor and a single dose of NVP syrup provided to the infant within 72 hours of birth. While most national guidelines specify that administration should occur in antenatal care facilities during a particular gestation period, healthcare providers have discovered that many women who have initial ANC visits early in gestational age do not return to the facilities later in their pregnancies. Accordingly,some countries now encourage healthcare providers to distribute the nevirapine tablet when pregnant women are diagnosed with HIV regardless of the gestational age. This document makes recommendations for using this strategy to prevent mother-to-child transmission of HIV. [HIV prevention and treatment guidelines change frequently based on clinical research study findings. Please refer to the WHO or U.S. DHHS guidelines for the most current recommendations on ARV treatment and PMTCT.]

Publisher: Elizabeth Glaser Pediatric AIDS Foundation
Language: English
Format: PDF
Regions: Global, Sub-Saharan Africa, South and Southeast Asia
Audiences: Policymakers, Program Managers, Researchers
Topic Areas: Antiretroviral Treatment & Complications, Perinatal Interventions
Resource Type: Program Best Practices